Insider Selling: Atreca, Inc. (NASDAQ:BCEL) CEO Sells $37,216.24 in Stock

Atreca, Inc. (NASDAQ:BCELGet Rating) CEO John A. Orwin sold 20,908 shares of the company’s stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $1.78, for a total transaction of $37,216.24. Following the transaction, the chief executive officer now owns 100,492 shares in the company, valued at $178,875.76. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Atreca Trading Down 6.7 %

Shares of NASDAQ:BCEL opened at $1.68 on Friday. The company has a market capitalization of $63.44 million, a price-to-earnings ratio of -0.58 and a beta of 0.69. Atreca, Inc. has a 12 month low of $1.51 and a 12 month high of $7.00. The firm’s 50-day moving average is $2.08 and its 200 day moving average is $2.24.

Atreca (NASDAQ:BCELGet Rating) last issued its earnings results on Monday, August 8th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.02). As a group, equities analysts forecast that Atreca, Inc. will post -2.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Atreca

Several hedge funds have recently modified their holdings of the business. Laurion Capital Management LP purchased a new stake in shares of Atreca in the 2nd quarter worth approximately $881,000. Millennium Management LLC lifted its position in Atreca by 2,858.4% during the second quarter. Millennium Management LLC now owns 395,071 shares of the company’s stock valued at $707,000 after acquiring an additional 381,717 shares during the last quarter. Renaissance Technologies LLC lifted its position in Atreca by 53.5% during the second quarter. Renaissance Technologies LLC now owns 560,800 shares of the company’s stock valued at $1,004,000 after acquiring an additional 195,400 shares during the last quarter. CM Management LLC lifted its position in Atreca by 50.0% during the second quarter. CM Management LLC now owns 225,000 shares of the company’s stock valued at $403,000 after acquiring an additional 75,000 shares during the last quarter. Finally, Gofen & Glossberg LLC IL lifted its position in Atreca by 66.7% during the second quarter. Gofen & Glossberg LLC IL now owns 25,000 shares of the company’s stock valued at $45,000 after acquiring an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 45.17% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Brookline Capital Management reiterated a “buy” rating on shares of Atreca in a report on Monday, August 8th.

About Atreca

(Get Rating)

Atreca, Inc, a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Featured Articles

Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.